In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Shaping The Medical Industry, December 2012

Executive Summary

Derived from Strategic Transactions, EBI’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals– and then categorized by type –Acquisition, Alliance, or Financing.

You may also be interested in...



CIR Expert Panel’s September Safety Findings, Final 2023 Priorities

Cosmetic Ingredient Review’s panel of independent experts will be highly focused on botanical ingredients in 2023 – a sign of the times, it says. At its September meeting, the panel finalized six ingredient safety reports, advanced four tentative reports, and issued an insufficient data announcement for Phenyl-Substituted Methicones.

US Regulatory Roundup – September 2022: Philips Troubles, Software And User Fees

The ten most popular stories about US regulatory issues published by Medtech Insight last month were a mixed bag, with a Philips recall taking the top spot and stories about AI, user fees, and more adding to the list.

Execs On The Move: Dentsply Gets New CEO And CFO

An interactive view of medtech executive changes from the month of September 2022. Major changes include Dentsply's appointment of a new CEO and CFO, a new CTO at Accuray and a re-shuffle at Pulse Biosciences.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV003790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel